Cargando…

Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy

Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab affected its efficacy. The correlation between wei...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikoma, Tatsuki, Matsumoto, Toshihiko, Kurioka, Yusuke, Takatani, Masahiro, Nagai, Hiroki, Matsumoto, Yusuke, Satake, Hironaga, Yasui, Hisateru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605511/
https://www.ncbi.nlm.nih.gov/pubmed/36294421
http://dx.doi.org/10.3390/jcm11206100
_version_ 1784818085488754688
author Ikoma, Tatsuki
Matsumoto, Toshihiko
Kurioka, Yusuke
Takatani, Masahiro
Nagai, Hiroki
Matsumoto, Yusuke
Satake, Hironaga
Yasui, Hisateru
author_facet Ikoma, Tatsuki
Matsumoto, Toshihiko
Kurioka, Yusuke
Takatani, Masahiro
Nagai, Hiroki
Matsumoto, Yusuke
Satake, Hironaga
Yasui, Hisateru
author_sort Ikoma, Tatsuki
collection PubMed
description Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab affected its efficacy. The correlation between weight change and nutritional status up to the start of nivolumab treatment and OS and progression-free survival (PFS) after starting nivolumab treatment was determined. Nutritional status was examined using the C-reactive protein/albumin ratio (CAR). A loss in body weight (LBW) from the onset of the first treatment of <4.5% led to OS prolongation and improved PFS outcomes. The median OS values in the LBW < 4.5% and ≥4.5% groups were 11.4 and 3.6 months, respectively. Similarly, changes in CAR from first-line chemotherapy (ΔCAR) affected OS; the ΔCAR < 0.01 group had a better prognosis than the ΔCAR ≥ 0.01 group. The median OS values in the ΔCAR < 0.01 and ≥0.01 groups were 9.4 and 4.5 months, respectively. The median OS in the group with LBW < 4.5% and ΔCAR < 0.01 was 12.9 months. LBW and deterioration of nutritional status following first-line chemotherapy are poor prognostic factors in AGC patients who received nivolumab as third- or later-line therapy. Early intervention to maintain body weight and nutritional status may improve the efficacy of immune checkpoint inhibitors.
format Online
Article
Text
id pubmed-9605511
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96055112022-10-27 Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy Ikoma, Tatsuki Matsumoto, Toshihiko Kurioka, Yusuke Takatani, Masahiro Nagai, Hiroki Matsumoto, Yusuke Satake, Hironaga Yasui, Hisateru J Clin Med Article Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab affected its efficacy. The correlation between weight change and nutritional status up to the start of nivolumab treatment and OS and progression-free survival (PFS) after starting nivolumab treatment was determined. Nutritional status was examined using the C-reactive protein/albumin ratio (CAR). A loss in body weight (LBW) from the onset of the first treatment of <4.5% led to OS prolongation and improved PFS outcomes. The median OS values in the LBW < 4.5% and ≥4.5% groups were 11.4 and 3.6 months, respectively. Similarly, changes in CAR from first-line chemotherapy (ΔCAR) affected OS; the ΔCAR < 0.01 group had a better prognosis than the ΔCAR ≥ 0.01 group. The median OS values in the ΔCAR < 0.01 and ≥0.01 groups were 9.4 and 4.5 months, respectively. The median OS in the group with LBW < 4.5% and ΔCAR < 0.01 was 12.9 months. LBW and deterioration of nutritional status following first-line chemotherapy are poor prognostic factors in AGC patients who received nivolumab as third- or later-line therapy. Early intervention to maintain body weight and nutritional status may improve the efficacy of immune checkpoint inhibitors. MDPI 2022-10-17 /pmc/articles/PMC9605511/ /pubmed/36294421 http://dx.doi.org/10.3390/jcm11206100 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ikoma, Tatsuki
Matsumoto, Toshihiko
Kurioka, Yusuke
Takatani, Masahiro
Nagai, Hiroki
Matsumoto, Yusuke
Satake, Hironaga
Yasui, Hisateru
Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
title Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
title_full Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
title_fullStr Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
title_full_unstemmed Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
title_short Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
title_sort improvement of body weight and nutritional status in gastric cancer patients enhances the benefit of nivolumab therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605511/
https://www.ncbi.nlm.nih.gov/pubmed/36294421
http://dx.doi.org/10.3390/jcm11206100
work_keys_str_mv AT ikomatatsuki improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy
AT matsumototoshihiko improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy
AT kuriokayusuke improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy
AT takatanimasahiro improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy
AT nagaihiroki improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy
AT matsumotoyusuke improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy
AT satakehironaga improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy
AT yasuihisateru improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy